A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax (ZE50-0134) in adults with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and select low-grade B-cell lymphomas. The study has two sequential parts. Part 1 uses dose escalation to determine the biologically effective dose and/or maximum tolerated dose of lonitoclax. Participants receive a 3-day step-up regimen followed by continuous once-daily or twice-daily oral dosing in 28-day c

Trial Details

NCT ID
NCT06708897
Phase
PHASE1
Sponsor
Lomond Therapeutics Holdings, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Lonitoclax (ZE50-0134)
Locations (sample)
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Cincinnati, Ohio, United States|39.12711,-84.51439
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Men and women aged 18 years or older.
  • Disease as defined below:
  • Part 1: Relapsed or refractory CLL or SLL, as defined by iwCLL, after at least 2 prior therapies that included a covalent Bruton tyrosine kinase in…
  • Part 2: Relapsed or refractory CLL or SLL, as defined by iwCLL, after at least 1 prior therapy that included a BTKi; participants must be venetocla…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →